Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients
Raquel Sainz-Amo, Alexander Rodero-Romero, Enric Monreal, Juan Luis Chico-García, Fernando Rodríguez-Jorge, Jose Ignacio Fernández-Velasco, Noelia Villarrubia, Jose Luis Veiga-González, Susana Sainz de la Maza, Jaime Masjuan, Lucienne Costa-Frossard, Luisa Maria Villar · 2024
Read Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients by Raquel Sainz-Amo, Alexander Rodero-Romero, Enric Monreal, Juan Luis Chico-García, Fernando Rodríguez-Jorge, Jose Ignacio Fernández-Velasco, Noelia Villarrubia, Jose Luis Veiga-González, Susana Sainz de la Maza, Jaime Masjuan, Lucienne Costa-Frossard, Luisa Maria Villar (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11642535.txt.
Description
Raquel Sainz-Amo and co-authors track blood markers under a strong multiple sclerosis drug in a 2024 study. Natalizumab calms relapsing MS powerfully. Two serum proteins report nerve damage and glial activation. Their course on treatment may grade response.
Fifty-four patients, mostly women in their thirties, were sampled at start, six, and twelve months. Seventy-six healthy controls set the reference. The nerve marker fell by about two-thirds within six months and more by a year. Patients free of disease activity dropped earlier and deeper. The glial marker also fell in the wider group. Blood tests may soon certify drug response without scans.
Catalog record
| CREATOR | Raquel Sainz-Amo, Alexander Rodero-Romero, Enric Monreal, Juan Luis Chico-García, Fernando Rodríguez-Jorge, Jose Ignacio Fernández-Velasco, Noelia Villarrubia, Jose Luis Veiga-González, Susana Sainz de la Maza, Jaime Masjuan, Lucienne Costa-Frossard, Luisa Maria Villar |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |